A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis.
Plaque psoriasis
Real world
Tildrakizumab
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
24
07
2022
accepted:
19
08
2022
pubmed:
9
9
2022
medline:
9
9
2022
entrez:
8
9
2022
Statut:
ppublish
Résumé
As with most medicines historically, clinicians prescribing tildrakizumab have relied on information derived from registration studies undertaken in a prospective controlled clinical trial setting. More recently, clinicians, policymakers, and commissioners increasingly rely on real-world data to inform both policy and practice. A retrospective real-world data study was undertaken at four specialist dermatology departments in the United Kingdom. All adult patients treated with tildrakizumab for moderate-to-severe plaque psoriasis were included, with data being collected for 122 patients. Psoriatic patients on tildrakizumab tended to be overweight (median body mass index of 32 (range 19-59) (n = 61); 26/68 (38%) < 90 kg, 32/68 (47%) between 90 and 120 kg, and 10/68 (15%) > 120 kg). The study population had high levels of comorbidities (83/116, 72%), multiple special sites (39/117, 33%), and histories of biological treatments (81/100, 81%). Most patients (61/80, 76%) initiated on tildrakizumab were switched from another biological treatment. Tildrakizumab was effective, with 91/122 (75%) patients remaining on treatment for the duration of the study-a median of 12 months per patient (range 1-29 months)-and achieving a change in median Psoriasis Area and Severity Index (PASI) from 12 to 0.35 and in Dermatology Life Quality Index (DLQI) from 20 to 0. The response rate was 57/66 (86%) when tildrakizumab was used as the first- or second-line biologic compared to 19/31 (61%) when used as the third- to seventh-line. Thirty-three (78.6%) patients over 90 kg of weight received the 200-mg dose of tildrakizumab. All but one (n = 8) patient with body weight over 120 kg maintained response over time. There was one treatment discontinuation; a patient who had a local sensitivity reaction. In UK clinical practice, tildrakizumab was well tolerated and effective at doses of 100 mg or 200 mg in a range of patient phenotypes.
Identifiants
pubmed: 36076145
doi: 10.1007/s13555-022-00800-3
pii: 10.1007/s13555-022-00800-3
pmc: PMC9458480
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2343-2354Informations de copyright
© 2022. The Author(s).
Références
Näslund-Koch C, Zachariae C, Skov L. Tildrakizumab: an evidence-based review of its use in the treatment of moderate-to-severe chronic plaque psoriasis. Ther Clin Risk Manag. 2020;24(16):903–16. https://doi.org/10.2147/TCRM.S227880 (PMID: 33061395; PMCID: PMC7522402).
doi: 10.2147/TCRM.S227880
Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–94. https://doi.org/10.1016/S0140-6736(14)61909-7 (Epub 2015 May 27 PMID: 26025581).
doi: 10.1016/S0140-6736(14)61909-7
pubmed: 26025581
WHO. World psoriasis day-document EB133.R2, agenda item 6.2. 2013. https://apps.who.int/gb/ebwha/pdf_files/EB133/B133_R2-en.pdf . Accessed 14 Apr 2022.
Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401–7. https://doi.org/10.1016/s0190-9622(99)70112-x (PMID: 10459113).
doi: 10.1016/s0190-9622(99)70112-x
pubmed: 10459113
Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152(5):861–7. https://doi.org/10.1111/j.1365-2133.2005.06502.x (PMID: 15888138).
doi: 10.1111/j.1365-2133.2005.06502.x
pubmed: 15888138
Gooderham MJ, Papp KA, Lynde CW. Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018;32(7):1111–9. https://doi.org/10.1111/jdv.14868 .
doi: 10.1111/jdv.14868
pubmed: 29438576
pmcid: 6033004
United States Food and Drug Administration. ILUMYA (tildrakizumab-asmn).2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf . Accessed 14 Apr 2022.
European Medicines Agency. Ilumetri EPAR. 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri . Accessed 14 Apr 2022.
Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology. 2021. https://doi.org/10.1159/000519924 (Epub ahead of print. PMID: 34775387).
doi: 10.1159/000519924
pubmed: 34775387
Wei NW, Chi S, Lebwohl MG. Retrospective analysis in patients with moderate to severe plaque psoriasis treated with tildrakizumab: real-life clinical data. J Psoriasis Psoriatic Arthritis. 2022;7(2):55–9. https://doi.org/10.1177/24755303221077211 .
doi: 10.1177/24755303221077211
Caldarola G, Galluzzo M, Bernardini N, Calabrese L, Grimaldi M, Moretta G, Pagnanelli G, Shumak RG, Talamonti M, Tofani L, Pallotta S, Peris K, Potenza C, De Simone C, Campione E. Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study. Dermatol Ther. 2022;35(6):e15488. https://doi.org/10.1111/dth.15488 (Epub 2022 Apr 11. PMID: 35384168; PMCID: PMC9287013).
doi: 10.1111/dth.15488
pubmed: 35384168
pmcid: 9287013
Poulin Y, Ramon M, Rosoph L, Weisman J, Mendelsohn AM, Parno J, Rozzo SJ, Lee P. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2020;34(7):1500–9. https://doi.org/10.1111/jdv.16187 (Epub 2020 Feb 9 PMID: 31919889).
doi: 10.1111/jdv.16187
pubmed: 31919889
Galluzzo M, Talamonti M, Cioni A, Maffei V, Shumak RG, Tofani L, Bianchi L, Campione E. Efficacy of tildrakizumab for the treatment of difficult-to-treat areas: scalp, nail, palmoplantar and genital psoriasis. J Clin Med. 2022;11(9):2631. https://doi.org/10.3390/jcm11092631 (PMID: 35566756; PMCID: PMC9100809).
doi: 10.3390/jcm11092631
pubmed: 35566756
pmcid: 9100809
Licata G, Danzuso GCL, Fiorella C, Palazzo G, Calzavara-Pinton P, Argenziano G, Gambardella A. Efficacy, safety and patient’s satisfaction for treatment of genital psoriasis with tildrakizumab: a case series and review of literature. J Eur Acad Dermatol Venereol. 2022. https://doi.org/10.1111/jdv.18368 (Epub ahead of print. PMID: 35758324).
doi: 10.1111/jdv.18368
pubmed: 35758324
Brunasso AM. Nail psoriasis improvement during tildrakizumab therapy: a real-life experience. J Drugs Dermatol. 2022;21(8):914–6. https://doi.org/10.36849/JDD.6828 .
doi: 10.36849/JDD.6828
pubmed: 35946963
Megna M, Tommasino N, Potestio L, Battista T, Ruggiero A, Noto M, Fabbrocini G, Genco L. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022. https://doi.org/10.1080/09546634.2022.2081655 (Epub ahead of print. PMID: 35603992.).
doi: 10.1080/09546634.2022.2081655
pubmed: 35875991
Office for National Statistics. Estimates of the population for the UK, England and Wales, Scotland, and Northern Ireland. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland . Accessed 14 Apr 2022
Duvetorp A, Mrowietz U, Nilsson M, Seifert O. Sex and age influence the associated risk of depression in patients with psoriasis: a retrospective population study based on diagnosis and drug-use. Dermatology. 2021;237(4):595–602. https://doi.org/10.1159/000509732 (Epub 2020 Sep 14. PMID: 32927456; PMCID: PMC8315676).
doi: 10.1159/000509732
pubmed: 32927456
Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33(9):1676–84. https://doi.org/10.1111/jdv.15653 (Epub 2019 Jun 27. PMID: 31054215; PMCID: PMC6771721).
doi: 10.1111/jdv.15653
pubmed: 31054215
pmcid: 6771721
Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2021;22(2):173–92. https://doi.org/10.1007/s40257-020-00578-0 (PMID: 33301128; PMCID: PMC7727454).
doi: 10.1007/s40257-020-00578-0
pubmed: 33301128